Heart Valve Company MitrAssist Raises $30M

November 9, 2017 | Israeli clinical stage biotech company MitrAssist has raised $30 million, in a funding round led by Fosun Pharma, the pharmaceutical arm of China-based pharmaceutical company Fosun International. China’s Ping Ang Insurance Company also contributed to the round. The heart valve company received $16 million according to its pre-closing valuation of $80 million. The company will also receive an additional $14 million according to a pre-closing valuation of $136 million when it begins clinical trials within a year. The Caesarea-based company developed a heart valve implant that can be installed through a thigh catheterization into an artery, without invasive heart surgery. The company was founded in 2009 by Gil Naor.